Sorafenib is tolerable and improves clinical outcomes in patients with FLT3-ITD acute myeloid leukemia prior to stem cell transplant and after relapse post-transplant

Sarah L. Sammons, Keith W. Pratz, B. Douglas Smith, Judith E. Karp, Ashkan Emadi

Research output: Contribution to journal › Letter › peer-review

30 Scopus citations

Fingerprint

Dive into the research topics of 'Sorafenib is tolerable and improves clinical outcomes in patients with FLT3-ITD acute myeloid leukemia prior to stem cell transplant and after relapse post-transplant'. Together they form a unique fingerprint.